Fratricide-resistant CD7 CAR-T therapy by NUS proves effective in treating relapsed or refractory T-cell leukaemia SINGAPORE, Oct. 5, 2024 /PRNewswire/ -- A new cell therapy, targeting CD7 onleukaemia ...

Antengene Corporation Limited (“ Antengene “, SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing ...

A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma. In the first study ...

A new study published in Cell Press reveals critical insights into the role of gamma-delta T cells across 33 cancer types, ...